Management of clinically inapparent adrenal mass

Lau J, Balk E, Rothberg M, Ioannidis J P A, DeVine D, Chew P, Kupelnik B, Miller K
Record ID 32002000430
English
Authors' objectives:

This report aims to assess the available evidence on the management of clinically inapparent adrenal mass. The widespread use of computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound imaging (US) has resulted in the incidental discovery of asymptomatic adrenal masses (also referred to as incidentaloma) that has created a management dilemma.

Authors' results and conclusions: Forty-five studies provided data about the prevalence of incidentaloma or the distribution of adrenal pathologies. Thirty-two studies evaluated diagnostic tests to differentiate adrenal masses. Over 80 studies provided outcome information on adrenal surgery techniques. Thirty-two studies reported prognostic information on patients with adrenal carcinoma after surgical excision, and nine articles reported follow-up results of untreated incidentaloma. Most of these studies were retrospective and the overall methodological quality was low. Because incidentaloma is not a disease entity, the prevalence of incidentaloma will vary with the circumstances. One study used transabdominal ultrasound for general health examination reported 11 verified adrenal masses out of 41,357 subjects (prevalence 0.027 percent). Combining individual cases from several studies, the prevalence of adenoma among incidentaloma was 41 percent, metastases 19 percent, adrenocortical carcinoma 10 percent, myelolipoma 9 percent, and pheochromocytoma 8 percent, and other mostly benign lesions comprised the remainder of the lesions. The distribution of pathology varies with the definition of incidentaloma applied. Most of the diagnostic studies were conducted for the purpose of diagnosing adrenal malignancy. In general, unenhanced or immediate enhanced CT had fair test characteristics. Delayed enhanced CT or MRI using the mass to spleen ratio had excellent test performance. Combined unenhanced CT with MRI improved the accuracy in one study. Scintigraphy had fair to excellent sensitivity and specificity. Fine needle aspiration had good to excellent test performance; however, inconclusive biopsies were common. In one small study, DHEAS had perfect sensitivity, but poor specificity. The clinical outcomes of various surgical adrenalectomy approaches were reassessed. Evidence suggests that laparoscopic adrenalectomy in general results in less blood loss and fewer major complications. The optimal surgical approach may depend on the size and the type of tumor. Limited follow-up data on patients with untreated incidentaloma found most tumors remain unchanged in size, some tumors disappeared or decreased in size, and about one-sixth of the tumors increased in size but none of these were adrenocortical carcinoma.
Authors' recommendations: With few exceptions, the overall methodological quality of the studies we examined was low. Future studies of incidentaloma need to broadly cover diverse manifestations of this condition but individual studies should apply rigorous inclusion criteria for each of the manifestations or provide thorough descriptions and careful analyses of well-defined subgroups. Future studies should incorporate rigorous methodologies to properly assess the clinical usefulness of various diagnostic tests and follow-up strategies for adrenal incidentalomas. An international registry of patients with well-documented adrenal incidentaloma may provide the best means of collecting these data.
Authors' methods: Systematic review
Details
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Adrenal Gland Neoplasms
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.